Abstract
As a result of intense genetic studies of families with specific mutations, the road to better therapeutic intervention for pheochromocytoma (PHEOs) and parangangliomas (PGLs) has more recently become populated with several promising molecular targets. Consequently a change in paradigm from a previous view on nonspecific therapy has shifted towards more selective molecular targeted therapies. In particular, malignant PHEOs/PGLs, more specifically the tumors that result from mutations in succinate dehydrogenase subunit B (SDHB), are a clear concern, and novel therapies should be developed to address this problem. Here we summarize current and future therapeutic approaches.
© Georg Thieme Verlag KG Stuttgart · New York.
MeSH terms
-
Adrenal Gland Neoplasms / drug therapy*
-
Adrenal Gland Neoplasms / genetics
-
Adrenal Gland Neoplasms / metabolism
-
Animals
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects
-
Cell Proliferation / drug effects
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Humans
-
Molecular Targeted Therapy
-
Neoplasm Proteins / antagonists & inhibitors
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism
-
Paraganglioma / drug therapy*
-
Paraganglioma / genetics
-
Paraganglioma / metabolism
-
Paraganglioma / secondary
-
Pheochromocytoma / drug therapy*
-
Pheochromocytoma / genetics
-
Pheochromocytoma / metabolism
-
Pheochromocytoma / secondary
-
Succinate Dehydrogenase / genetics*
-
Succinate Dehydrogenase / metabolism
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Neoplasm Proteins
-
SDHB protein, human
-
Succinate Dehydrogenase